Mangoceuticals raises $2.5 million through equity offering

Mangoceuticals, Inc. (NASDAQ: MGRX) announced it has entered into definitive agreements with institutional investors for a registered direct offering and concurrent private placement expected to generate approximately $2.5 million in gross proceeds.

The Dallas-based telemedicine company sold 1,930,502 units, each consisting of one share of common stock or one pre-funded warrant, plus one warrant to purchase one share of common stock at an exercise price of $1.4245. The offering price per unit was set at $1.295, with pre-funded units priced at $1.29499.

The pre-funded warrants are immediately exercisable and may be exercised at any time until exercised in full. The transaction was priced at market under NASDAQ rules.

The transactions are expected to close on or about December 19, 2025, subject to customary closing conditions. Mangoceuticals plans to use the net proceeds, combined with existing cash, for general corporate purposes and working capital.

Aegis Capital Corp. served as the exclusive placement agent for the offerings. The registered direct offering is being conducted under an effective shelf registration statement previously filed with the Securities and Exchange Commission.

The company operates telemedicine platforms under the brands MangoRx and PeachesRx, focusing on men's health and wellness products including treatments for erectile dysfunction, hair growth, hormone replacement therapies, and weight management.

The private placement securities were offered only to accredited investors and have not been registered under the Securities Act of 1933. The company has agreed to file registration statements with the SEC covering the resale of the securities issued in the private placement.

You May Also Be Interested In

• Matinas BioPharma to merge with GH Power, sell drug unit to Azurity
• Elong Power closes $6.6M public offering on Nasdaq
• Q32 Bio launches $200M stock offering to fund clinical trials